Medigen Biotechnology Total Assets

Latest as of September 2025: NT$6.34 Billion TWD ≈ $199.85 Million USD

Medigen Biotechnology total assets. Based on the latest financial reports, Medigen Biotechnology (3176) holds total assets worth NT$6.34 Billion TWD (≈ $199.85 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 3176 market cap overview for the company's overall valuation and market capitalisation.

Total Assets of Medigen Biotechnology (2003–2024)

Total assets of Medigen Biotechnology from 2003 to 2024. This chart illustrates how Medigen Biotechnology's total assets have evolved over time, based on quarterly financial data. See latest Medigen Biotechnology stock price today for real-time trading data and today's change.

Medigen Biotechnology - Asset Composition Analysis

Medigen Biotechnology Total Assets Breakdown (December 2024)

Medigen Biotechnology total assets breakdown as of December 2024. Medigen Biotechnology's total assets of NT$6.34 Billion consist of 54.6% current assets and 45.4% non-current assets.

Asset Category	Amount (TWD)	% of Total Assets
Cash & Equivalents	NT$0.00	20.7%
Accounts Receivable	NT$201.24 Million	3.0%
Inventory	NT$645.06 Million	9.6%
Property, Plant & Equipment	NT$0.00	0.0%
Intangible Assets	NT$0.00	0.0%
Goodwill	NT$0.00	0.0%

Asset Composition Trend (2003–2024)

This chart illustrates how Medigen Biotechnology's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 3176 net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Medigen Biotechnology's current assets represent 54.6% of total assets in 2024, an increase from 0.0% in 2003.
Cash Position: Cash and equivalents constituted 20.7% of total assets in 2024, up from 5.3% in 2003.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 47.0% in 2003.
Asset Diversification: The largest asset category is inventory at 9.6% of total assets.

Medigen Biotechnology Competitors by Total Assets

Key competitors of Medigen Biotechnology based on total assets are shown below.

Company	Country	Total Assets
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	USA	$1.26 Billion
Verona Pharma plc F:I9SA	Germany	€572.87 Million
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	USA	$641.76 Million
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	China	CN¥37.46 Billion
Metsera, Inc. Common Stock NASDAQ:MTSR	USA	$639.66 Million
Beijing Tiantan Biological Products Corp Ltd SHG:600161	China	CN¥16.55 Billion
Bavarian Nordic CO:BAVA	Denmark	Dkr14.95 Billion
Hebei Changshan Biochem Pharma SHE:300255	China	CN¥4.66 Billion

Medigen Biotechnology - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	5.12	4.07	3.24
Quick Ratio	4.16	3.38	2.89
Cash Ratio	0.00	0.00	0.00
Working Capital	NT$2.86 Billion	NT$2.77 Billion	NT$2.09 Billion

Medigen Biotechnology - Advanced Valuation Insights

This section examines the relationship between Medigen Biotechnology's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	2.69
Latest Market Cap to Assets Ratio	0.02
Asset Growth Rate (YoY)	-21.3%
Total Assets	NT$6.71 Billion
Market Capitalization	$141.32 Million USD

Valuation Analysis

Below Book Valuation: The market values Medigen Biotechnology's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: Medigen Biotechnology's assets decreased by 21.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Medigen Biotechnology (2003–2024)

The table below shows the annual total assets of Medigen Biotechnology from 2003 to 2024.

Year	Total Assets	Change
2024-12-31	NT$6.71 Billion ≈ $211.42 Million	-21.31%
2023-12-31	NT$8.53 Billion ≈ $268.65 Million	-14.58%
2022-12-31	NT$9.98 Billion ≈ $314.50 Million	+21.74%
2021-12-31	NT$8.20 Billion ≈ $258.33 Million	+33.27%
2020-12-31	NT$6.15 Billion ≈ $193.84 Million	+27.41%
2019-12-31	NT$4.83 Billion ≈ $152.13 Million	+5.01%
2018-12-31	NT$4.60 Billion ≈ $144.87 Million	-5.60%
2017-12-31	NT$4.87 Billion ≈ $153.46 Million	+1.01%
2016-12-31	NT$4.82 Billion ≈ $151.93 Million	+7.30%
2015-12-31	NT$4.49 Billion ≈ $141.60 Million	+0.69%
2014-12-31	NT$4.46 Billion ≈ $140.62 Million	+35.49%
2013-12-31	NT$3.29 Billion ≈ $103.79 Million	+47.04%
2012-12-31	NT$2.24 Billion ≈ $70.59 Million	+84.46%
2011-12-31	NT$1.21 Billion ≈ $38.27 Million	+39.64%
2010-12-31	NT$869.78 Million ≈ $27.40 Million	+28.05%
2009-12-31	NT$679.27 Million ≈ $21.40 Million	-0.25%
2008-12-31	NT$680.98 Million ≈ $21.45 Million	+14.83%
2007-12-31	NT$593.03 Million ≈ $18.68 Million	-20.17%
2006-12-31	NT$742.89 Million ≈ $23.41 Million	+5.80%
2005-12-31	NT$702.17 Million ≈ $22.12 Million	-8.52%
2004-12-31	NT$767.53 Million ≈ $24.18 Million	-20.61%
2003-12-31	NT$966.81 Million ≈ $30.46 Million	--

About Medigen Biotechnology

TWO:3176 Taiwan Biotechnology

Market Cap

$141.32 Million

NT$4.49 Billion TWD

Market Cap Rank

#17697 Global

#911 in Taiwan

Share Price

NT$32.20

Change (1 day)

+1.26%

52-Week Range

NT$28.75 - NT$39.90

All Time High

NT$102.50